Paroxysmal nocturnal hemoglobinuria

Jun 12, 2020

EHA25Virtual: Pegcetacoplan, a Novel C3 Complement Inhibitor - Beginning of a New Era in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)

May 14, 2020

Paroxysmal Nocturnal Hemoglobinuria Markets and Pipeline Analysis: 2016-2019 & 2020-2024

Dec 05, 2019

Regeneron Announces Positive Topline Phase 2 Data with Anti-C5 Antibody Pozelimab in Patients with a Rare Blood Disorder

Jun 26, 2019

Global paroxysmal nocturnal hemoglobinuria (PNH) treatment market is expected to grow with a CAGR of 11.6% over the forecast period from 2019-2025

Jun 10, 2019

PNH Treatment Market Size Worth $5.8 Billion by 2025 | CAGR: 11.2%: Grand View Research, Inc.

Feb 05, 2019

The Canadian Association of PNH Patients (PNHCA) and Backpack Health Collaborate to Connect Patients with Resources, Research and Community

Dec 21, 2018

FDA approves new treatment for adult patients with rare, life-threatening blood disease

Oct 09, 2018

Global Paroxysmal Nocturnal Hemoglobinuria Market and Competitive Landscape 2014-2018 & Forecast to 2023

Oct 18, 2017

Global Hematological Disorders Market 2017 - Innovative First-in-Class Product Developments Remain Attractive

Jun 29, 2017

Positive Data from APL-2 Studies Show Rapid and Durable Improvements in LDH and Hemoglobin Levels in PNH